Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo in pediatric hypermutant cancers
NCT02992964Phase 2Terminated
- Sponsor
- SickKids
- Start
- May 2017
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label trial of nivolumab in malignant neoplasm and biallelic mismatch repair deficiency syndrome (BMMRD), sponsored by SickKids. Primary endpoint: Objective Response Rate at 60 months. Started May 2017; status: terminated.
02
Drugs
03
Conditions
malignant neoplasmbiallelic mismatch repair deficiency syndrome (BMMRD)
Beyond the preview
Go deeper on NCT02992964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992964.